The RUNX genes: gain or loss of function in cancer

K Blyth, ER Cameron, JC Neil - Nature Reviews Cancer, 2005 - nature.com
The RUNX genes have come to prominence recently because of their roles as essential
regulators of cell fate in development and their paradoxical effects in cancer, in which they …

Genetics of myeloid malignancies: pathogenetic and clinical implications

S Fröhling, C Scholl, DG Gilliland… - Journal of clinical …, 2005 - ascopubs.org
Myeloid malignancies are clonal disorders that are characterized by acquired somatic
mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic …

Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia

SE Mullican, S Zhang, M Konopleva, V Ruvolo… - Nature medicine, 2007 - nature.com
Abstract Nur77 (NR4A1) and Nor-1 (NR4A3) are highly homologous orphan nuclear
receptors, that regulate the transcription of overlapping target genes,. The transcriptional …

Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7

A Nagamachi, H Matsui, H Asou, Y Ozaki, D Aki… - Cancer cell, 2013 - cell.com
Monosomy 7 and interstitial deletion of 7q (− 7/7q−) are well-recognized nonrandom
chromosomal abnormalities frequently found among patients with myelodysplastic …

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

F Basheer, G Giotopoulos, E Meduri, H Yun… - Journal of Experimental …, 2019 - rupress.org
Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function
EZH2 mutations are common in myeloid malignancies. We have examined the importance …

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

A Burchert, Y Wang, D Cai, N Von Bubnoff, P Paschka… - Leukemia, 2005 - nature.com
BCR/ABL-kinase mutations frequently mediate clinical resistance to the selective tyrosine
kinase inhibitor Imatinib mesylate (IM, Gleevec®). However, mechanisms that promote …

Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity

SL Goldman, C Hassan, M Khunte, A Soldatenko… - Frontiers in …, 2019 - frontiersin.org
Leukemia, specifically acute myeloid leukemia (AML), is a common malignancy that can be
differentiated into multiple subtypes based on leukemogenic history and etiology. Although …

Addiction of t (8; 21) and inv (16) acute myeloid leukemia to native RUNX1

O Ben-Ami, D Friedman, D Leshkowitz, D Goldenberg… - Cell reports, 2013 - cell.com
Summary The t (8; 21) and inv (16) chromosomal aberrations generate the oncoproteins
AML1-ETO (AE) and CBFβ-SMMHC (CS). The role of these oncoproteins in acute myeloid …

A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice

A Illendula, JA Pulikkan, H Zong, J Grembecka, L Xue… - Science, 2015 - science.org
Acute myeloid leukemia (AML) is the most common form of adult leukemia. The transcription
factor fusion CBFβ-SMMHC (core binding factor β and the smooth-muscle myosin heavy …

Chromosomal translocations: revisited yet again

JD Rowley - Blood, The Journal of the American Society of …, 2008 - ashpublications.org
It is hard today, in 2008, when genetic changes in cancer and specifically hematologic
malignancies are accepted as central players, to look back 50 years and realize how …